Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-LILRA6 CAR-T cells
- Development stage
- Phase 1
- Lead developer
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
anti-LILRA6 CAR-T cells is an autologous chimeric antigen receptor (CAR) T-cell therapy being developed by the Second Affiliated Hospital, School of Medicine, Zhejiang University for the treatment of relapsed or refractory acute myeloid leukemia (AML). The therapy involves the genetic modification of a patient's peripheral blood-derived T cells using a lentiviral vector to express a CAR targeting the Leukocyte Immunoglobulin Like Receptor A6 (LILRA6) protein. LILRA6 is an activating receptor that is often overexpressed on AML blasts. Once infused back into the patient, these engineered T cells recognize and eliminate LILRA6-positive leukemic cells through direct cytotoxicity. The drug is currently being evaluated in a Phase I dose-escalation and expansion clinical study to assess its safety and efficacy in adult patients.
- Other names
- LILRA6 CAR-T cellsLILRA-6 CAR-T cellsLILRA 6 CAR-T cellsLILRA6-directed chimeric antigen receptor T cellsLILRA-6-directed chimeric antigen receptor T cellsLILRA 6-directed chimeric antigen receptor T cellsAnti-LILRA6 CAR-T cellsAnti-LILRA-6 CAR-T cellsAnti-LILRA 6 CAR-T cells
02
Targets
LILRA6 (Leukocyte immunoglobulin-like receptor subfamily A member 6)
Beyond the preview
Go deeper on anti-LILRA6 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-LILRA6 CAR-T cells.